



Structural Content

12:00 - 12:05	<p>INTRODUCTIONS & LEARNING OBJECTIVES</p> <p>Dr. Anita Asgar & Dr. David Wood</p>
12:05 - 12:10	<p>MESSAGE FROM THE I2C CHAIR</p> <p>Dr. Minh Vo</p>
12:10 - 12:40	<p>HOW SHOULD I TREAT THE LEFT ATRIAL APPENDAGE?</p> <p>Case Presenter: Dr. Jean-Bernard Masson Panelists: Dr. Jackie Saw & Dr. Mark Osten</p> <p>At the completion of this session participants will be able to clearly define which patient populations derive maximal clinical benefit from a left atrial appendage intervention and the agreed best clinical practice.</p>
12:40 - 13:10	<p>HOW SHOULD I TREAT PATIENTS WITH SYMPTOMATIC MITRAL REGURGITATION?</p> <p>Case Presenter: Dr. Kevin Bainey Panelists: Dr. Robert Boone & Dr. Shahar Lavi</p> <p>At the completion of this session participants will be able to distinguish and critically evaluate the established clinical management strategies for patients diagnosed with symptomatic mitral regurgitation.</p>
13:10 - 13:40	<p>WHAT ANTITHROMBOTIC AGENT SHOULD I USE POST TAVI?</p> <p>Case Presenter: Dr. Malek Kass Panelists: Dr. Rob Welsh & Dr. John Webb</p> <p>At the completion of this session, participants will be able to assess the published literature, agreed best practice and assimilate that acumen into their clinical practice.</p>
13:40 - 13:55	REFRESHMENT BREAK - EMERALD BALLROOM FOYER
13:55 - 14:25	<p>WHICH VALVE PLATFORM FOR WHICH INTERMEDIATE RISK PATIENT: THE GREAT VALVE DEBATE.</p> <p>Debaters: Dr. John Webb & Dr. Sam Radhakrishnan</p> <p>At the completion of this debate, participants will be able to more effectively distinguish which intermediate risk patients will derive maximal clinical benefit from specific valve platforms.</p>
14:25 - 14:30	<p>EVALUATIONS & MEETING CLOSE</p> <p>Dr. Anita Asgar & Dr. David Wood</p>

14:30 - 15:00

WELCOME RECEPTION - EMERALD BALLROOM FOYER

Coronary Content

15:00 - 15:05

INTRODUCTIONS & LEARNING OBJECTIVES

Dr. Hung Ly & Dr. Kevin Bainey

15:05 - 15:10

MESSAGE FROM THE CAIC PRESIDENT

Dr. Warren Cantor

15:10 - 15:25

PCSK9 PRESENTATION (INTERPLAY BETWEEN CORONARY DISEASE AND LIPID MANAGEMENT)

Dr. Todd Anderson

At the completion of this session participants will be able to critically evaluate the body of evidence defining the clinical relationship between lipid management and coronary artery disease.

15:25 - 15:40

EVOLVING STENT PLATFORMS

Dr. J.F. Tanguay

At the completion of this session participants will be able to restate the body of clinical evidence for the use of evolving stent platforms in patients diagnosed with a coronary artery occlusion.

15:40 - 16:10

INTERVENTIONAL PHARMACOTHERAPY: DURATION OF DAPT CASE

Case Presenter: Dr. Matt Sibbald

Panelists: Dr. Rob Welsh & Dr. John Cairns

At the completion of this session participants will be able to translate the current duration of DAPT therapy evidence into their daily practice.

16:10 - 16:40

INTERVENTIONAL PHARMACOTHERAPY: TRIPLE THERAPY CASE

Case Presenter: Dr. Brian Potter

Panelists: Dr. Rob Welsh & Dr. John Cairns

At the completion of this session participants will be able to more effectively define the most appropriate clinical scenario within which triple therapy should be prescribed for patients diagnosed with Afib and an ACS.

16:40 - 17:10

COMPLEX CORONARY INTERVENTIONS: LM PCI WITH PVAD SUPPORT CASE

Case Presenter: Dr. Vlad Dzavik

Panelists: Dr. Don Palisaitis & Dr. James Velianou

At the completion of this session participants will be able to cite and critique the established management strategies when performing a complex left main PCI.

Coronary Content

17:10 - 17:40	<p>COMPLEX CORONARY INTERVENTIONS: LASER TREATMENT FOR SEVERE IN-STENT RESTENOSIS</p> <p>Case Presenter: Dr. Simon Robinson Panelists: Dr. Hung Ly & Dr. Amir Ravandi</p> <p>At the completion of this session participants will be able to define the optimal clinical scenario of when to employ laser technology for the management of an in-stent thrombosis.</p>
17:40 - 17:55	<p>IFR/FFR CASE PRESENTATION</p> <p>Dr. Erick Schampaert</p> <p>At the completion of this session participants will be able to illustrate the most appropriate clinical scenario within which iFR/FFR can be used to evaluate the clinical significance of coronary lesions.</p>
17:55 - 18:00	<p>EVALUATIONS & MEETING CLOSE</p> <p>Dr. Hung Ly & Dr. Kevin Bainey</p>
18:00 - 20:30	<p>GROUP DINNER</p>
18:30	<p>KEYNOTE PRESENTATION - Dr. Merrill Knudtson</p>



Canadian Cardiovascular Society

Leadership. Knowledge. Community.

This event is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program. This program is approved by the Canadian Cardiovascular Society for a maximum of 5 credits.

Canadian Association of
Interventional Cardiology



Association Canadienne
de cardiologie d'intervention